BioNTech (NASDAQ:BNTX) Shareholders Have Earned a 47% CAGR Over the Last Five Years
BioNTech (NASDAQ:BNTX) Shareholders Have Earned a 47% CAGR Over the Last Five Years
We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to find, but they can generate massive returns over long periods. For example, the BioNTech SE (NASDAQ:BNTX) share price is up a whopping 569% in the last half decade, a handsome return for long term holders. If that doesn't get you thinking about long term investing, we don't know what will. Also pleasing for shareholders was the 29% gain in the last three months. Anyone who held for that rewarding ride would probably be keen to talk about it.
我們認爲所有投資者都應該嘗試買入並持有高質量的多年贏家。雖然最好的公司很難找到,但它們可以在長時間內產生巨大的回報。例如,BioNTech SE(納斯達克:BNTX)的股價在過去的半個十年裏飆升了569%,對於長揸者來說是一筆可觀的回報。如果這不能讓您考慮長期投資,我們不知道還有什麼能。股東們也高興地看到最近三個月的漲幅達到了29%。任何持有股票的人可能會很樂意談論這段值得回味的旅程。
With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.
鑑於此,值得看看該公司的基本面是否一直是長期業績的驅動因素,或者是否存在一些不一致之處。
BioNTech isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
BioNTech目前不盈利,因此大多數分析師會關注營業收入增長,以了解底層業務增長速度。當一家公司沒有盈利時,我們通常希望看到良好的營業收入增長。這是因爲快速的營業收入增長可以輕鬆推算出可觀規模的利潤。
In the last 5 years BioNTech saw its revenue grow at 26% per year. That's well above most pre-profit companies. Arguably, this is well and truly reflected in the strong share price gain of 46%(per year) over the same period. Despite the strong run, top performers like BioNTech have been known to go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.
在過去5年裏,BioNTech的營業收入每年增長26%。這遠超大多數未盈利公司。可以說,這完全反映在了同期46%的強勁股價漲幅中。儘管股價大漲,BioNTech等表現出色的公司卻一直以來都被認爲是勝利者。從表面上看,這看起來是一個不錯的機會,儘管我們注意到市場情緒已經非常積極。
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。
It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. If you are thinking of buying or selling BioNTech stock, you should check out this free report showing analyst profit forecasts.
值得注意的是,CEO的薪酬低於類似規模公司的中位數。關注CEO的薪酬總是重要的,但更重要的問題是公司未來是否會持續增長收益。如果您考慮購買或出售biontech股票,您應該查看這份顯示分析師盈利預測的免費報告。
What About The Total Shareholder Return (TSR)?
那麼,股東總回報(TSR)呢?
We've already covered BioNTech's share price action, but we should also mention its total shareholder return (TSR). The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. BioNTech hasn't been paying dividends, but its TSR of 575% exceeds its share price return of 569%, implying it has either spun-off a business, or raised capital at a discount; thereby providing additional value to shareholders.
我們已經涵蓋了biontech的股價走勢,但我們也應該提到其總股東回報率(TSR)。TSR是一種回報計算,考慮到現金分紅的價值(假設任何獲得的股息都被再投資)以及任何折現後的增資和拆分的計算價值。biontech還沒有支付分紅股息,但其575%的TSR超過了569%的股價回報率,這意味着它可能拆分了一家業務,或以折扣方式進行了資本增發;從而爲股東提供了額外的價值。
A Different Perspective
不同的觀點
BioNTech provided a TSR of 21% over the last twelve months. But that return falls short of the market. If we look back over five years, the returns are even better, coming in at 47% per year for five years. Maybe the share price is just taking a breather while the business executes on its growth strategy. It's always interesting to track share price performance over the longer term. But to understand BioNTech better, we need to consider many other factors. For instance, we've identified 1 warning sign for BioNTech that you should be aware of.
biontech在過去12個月內提供了21%的TSR。但這個回報率低於市場。如果我們回顧5年的時間,回報率甚至更好,達到每年47%的水平。也許股價只是在業務執行其增長策略時稍作停頓。長期跟蹤股價表現總是很有趣。但要更好地了解biontech,我們需要考慮許多其他因素。例如,我們已經確認了您應該注意的1個biontech警告信號。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。